NCCN临床实践指南_骨髓增殖性肿瘤(2019.V3)英文版
96页1、Myeloproliferative Neoplasms Version 3 2019 September 4 2019 NCCN org NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Version 3 2019 09 04 19 National Comprehensive Cancer Network Inc 2019 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN Continue Aaron T Gerds MD MS Chair Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institu
2、te Jason Gotlib MD MS Vice Chair Stanford Cancer Institute Prithviraj Bose MD The University of Texas MD Anderson Cancer Center Michael W Deininger MD PhD Huntsman Cancer Institute at the University of Utah Ivana Gojo MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Krishna Gundabolu MBBS Fred MPN 10 MPN C 2 of 2 Prognostic Significance of Mutations in MPN MPN D IWG MRT Diagnostic Criteria for Post PV Post ET MF MPN E Special Considerations for the Use of JAK Inhibitors Ruxoliti
3、nib MPN F 2 of 4 and Fedratinib MPN F 4 of 4 Special Considerations in the Treatment of PV and ET MPN G Definition of Resistance Intolerance to Hydroxyurea MPN H Clinical Trials NCCN believes that the best management for any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged To find clinical trials online at NCCN Member Institutions click here nccn org clinical trials clinicians aspx NCCN Categories of Evidence and Consensus All recommendations a
4、re category 2A unless otherwise indicated See NCCN Categories of Evidence and Consensus The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment The National Comprehensive Cancer Network NCCN makes no repr
5、esentations or warranties of any kind regarding their content use or application and disclaims any responsibility for their application or use in any way The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network All rights reserved The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN 2019 NCCN Guidelines Index Table of Contents Discussion Version 3 2019 09 04 19 National Comprehensive Cancer Network I
《NCCN临床实践指南_骨髓增殖性肿瘤(2019.V3)英文版》由会员沧海****3分享,可在线阅读,更多相关《NCCN临床实践指南_骨髓增殖性肿瘤(2019.V3)英文版》请在金锄头文库上搜索。
洁厕灵企业技术标准范例
发电企业热工设备检修规程
发电企业热控日常点检标准
发电企业汽机(含燃机)技术监督细则
发电企业电气设备保护及安全自动装置投退和定值变更管理标准
继电保护定值变更通知单
继电保护及安全自动装置投退审批表
电气保护定值更改申请单
化工企业粉尘涉爆企业整体安全风险等级评估方法
化工企业安全检查管理规程
电气安全管理规程范例
农业企业绿色食品大棚生菜生产操作规程
农业企业绿色食品桃园管理规程
农业企业绿色食品早春蕹菜生产操作规程
农业企业绿色食品大棚蚕豆促早栽培生产技术操作规程
农业企业绿色食品荠菜种植规程
农业企业绿色食品青椒种植规程
农业企业绿色食品筒篙种植规程
农业企业绿色食品油麦菜种植规程
农业企业绿色食品木耳菜种植规程
2023-05-11 11页
2022-09-05 10页
2022-08-18 10页
2022-08-18 6页
2022-08-18 7页
2022-08-18 3页
2022-08-18 5页
2022-08-18 9页
2022-08-18 7页
2022-08-18 4页